Introduction
One approach to cancer treatment is to enhance tumor suppressor activity in tumors. The effectiveness of this strategy has been recently shown using genetically engineered mouse models, in which restoration of expression of a tumor suppressor, in this case p53, led to complete tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007) . This approach is currently not feasible in humans, the primary limitation being that most known tumor suppressors are mutated or deleted in tumors. The CDK inhibitor p27 Kip1 (p27) is a notable exception to the classic tumor suppressor gene paradigm as the CDKN1B gene that encodes p27 is rarely mutated in tumors (Kawamata et al., 1995; PonceCastaneda et al., 1995) . Instead, the levels of p27 protein are reduced or mislocalized, and this correlates with tumor aggressiveness and poor prognosis (Chu et al., 2008) . A causal role for p27 in tumor suppression has been shown by the increased susceptibility of p27-deficient mice to tumor development (Fero et al., 1996 (Fero et al., , 1998 Kiyokawa et al., 1996; Nakayama et al., 1996) . The fact that the gene encoding p27 remains intact in most human cancers provides an opportunity to design therapies that might enhance expression of p27. Key elements to the success of this strategy are to understand the mechanism(s) leading to misexpression of p27 and determine whether manipulating these pathways can enhance nuclear p27 expression in tumors. p27 abundance is regulated by a number of different pathways throughout the cell cycle. The levels of p27 are high in quiescent cells and markedly reduced as cells transit through the cell cycle. In S phase, p27 is phosphorylated at Thr187 by CDK2, targeting p27 for ubiquitination by SKP2 and subsequent degradation by the proteasome (Sheaff et al., 1997) . The KPC ubiquitin ligase was recently identified as a second mechanism to target p27 for degradation during G1 (Kamura et al., 2004) . Microinjection studies showed that active Ras can reduce p27 by three pathways: MAPK in G1, PI3K in G1 and S, and through increased SKP2 in S and G2 (Sa and Stacey 2004) . Colorectal cancer cell lines exhibit proteasome-dependent degradation of p27 (Loda et al., 1997) , and many tumors express high levels of the ubiquitin ligase, SKP2, suggesting that the levels of p27 in tumors are regulated by proteasomal degradation (Bloom and Pagano 2003) . Recent studies revealed that non-receptor tyrosine kinases, such as Src, phosphorylate p27, consequently decreasing its stability (Chu et al., 2007; Grimmler et al., 2007) , which may be yet another mechanism to reduce p27 abundance in tumors.
In addition to decreasing overall p27 levels, exclusion of p27 from the nucleus and retention in the cytoplasm can effectively reduce its CDK-inhibitory activity. Cancers of the breast, thyroid, esophagus and colon show specific reduction in nuclear p27, suggesting that p27 mislocalization may be important for tumor progression (Blain and Massague 2002) . At least two pathways have been proposed for nuclear export of p27 during G1 and S phase: association with Jab1, a component of the COP9-signalosome complex (Tomoda et al., 1999) , or direct binding to the transporter CRM1 through the nuclear export signal of p27 (Connor et al., 2003) . Nuclear export is regulated by the phosphorylation of p27 at specific residues. Ser10 phosphorylation of p27 by human kinase-interacting stathmin (hKIS or KIST) increases the binding of p27 to the nuclear exporter CRM1 (Boehm et al., 2002) . Experiments utilizing knockin mice carrying a Ser-to-Ala mutation at position 10 of p27 showed reduced levels of p27 in cultured mouse embryonic fibroblasts (Kotake et al., 2005) and impaired nuclear export of p27 (Besson et al., 2006) . Phosphorylation of Thr198, by either Akt or RSK1/2, results in binding to the protein 14-3-3 and retention in the cytoplasm (Fujita et al., 2003) . This increases the stability of p27 by preventing proteasomal turnover (Kossatz et al., 2006) . Cytoplasmic retention of p27 in human breast cancer cells was shown to be regulated by phosphorylation of Thr157 by the Akt kinase (Liang et al., 2002; Viglietto et al., 2002; Shin et al., 2005) . However, Thr157 is not present in rodent p27, therefore this pathway is not evolutionarily conserved.
p27 is also regulated at the transcriptional levels. In quiescent cells, FOXO proteins are located within the nucleus in which they bind to the p27 promoter and initiate transcription (Dijkers et al., 2000) . In response to growth factors or oncogenic signals, FOXO proteins are phosphorylated by Akt, resulting in cytoplasmic sequestration, decreased p27 transcription and cell proliferation . As Akt is active in many tumors, this may represent an additional mechanism to reduce p27 during tumor growth.
Lung cancer is among the leading causes of death worldwide, and non-small-cell lung cancer (NSCLC) accounts for B87% of these cases (Singhal et al., 2005) . Reduced expression of p27 is seen in B30% of NSCLC cases, and five independent studies have shown a significant correlation of reduced p27 with disease recurrence or death (Chu et al., 2008) . Mutations in Kras and EGFR are frequently seen in lung cancer (Ding et al., 2008) and signaling from either can downregulate p27 in cell lines (Busse et al., 2000; Sa and Stacey 2004) . Inui et al. (2003) reported that p27 mRNA levels were not reduced in lung tumors, although these were not stratified by Ras mutational status or Akt activity. Catzavelos et al. reported that Ras mutation and p27 expression seem to occur independently in adenocarcinoma of the lung. Thus, the mechanism(s) contributing to altered regulation of p27 during lung tumorigenesis are unclear.
Urethane treatment of mice induces alveolar/bronchiolar adenomas and adenocarcinomas, which closely resemble human NSCLC adenocarcinoma in morphological and molecular characteristics (Malkinson 2001) . In this study, we use this murine lung model model to examine the role of p27 in lung tumor suppression and the mechanisms leading to its misregulation.
Results

p27-deficient mice are susceptible to NSCLC
To establish an autochthonous tumor model to examine the role of p27 in lung cancer, cohorts of p27 þ / þ , þ /À and À/À littermates were injected with urethane. The lung tumor incidence for all three genotypes was 100% at both 30 and 50 weeks. At 30 weeks, both tumor multiplicity and size were significantly greater in p27À/À and þ /À mice compared with those in wild-type littermates ( Figure 1a ). The average number of tumors greater than 1 mm in diameter was 1.4±1.87, 4.2±3.5 and 7.0±4.5 for p27 þ / þ , þ /À and À/À mice, respectively (P hetÀwt ¼ 0.026; P nullÀwt ¼ 0.0012; twotailed t-test). Only four p27À/À mice survived beyond 40 weeks of age (median age 46 weeks), due to complications arising from excess lung tumor burden and pituitary tumors, and data from these four mice are included in the 50-week graph (Figure 1b) . Tumor burden was greater at 50 versus 30 weeks for all genotypes. Again, tumor multiplicity and size were both increased in p27-deficient mice compared with those in wild-type littermates (Figures 1b-d) . The average number of tumors per mouse at 50 weeks of age in p27-intact mice was similar to the number in p27À/À mice at 30 weeks of age (Figure 1c) , suggesting that the primary effect of p27 is to inhibit tumor growth as opposed to tumor initiation.
As the tumor burden of p27 þ /À mice was increased relative to p27 þ / þ mice, we examined the cdkn1b locus for loss of heterozygosity. Analysis of tumors from p27 þ /À mice showed retention of the wild-type cdkn1b allele in all 24 tumors examined (Figure 1e ), consistent with previous findings that p27 is haploinsufficient for tumor suppression (Fero et al., 1998) .
Histological evaluation revealed that the majority of tumors were alveolar/bronchiolar adenomas that displayed papillary, solid or mixed morphologies. In p27-intact mice, adenocarcinomas were not seen until 50 weeks of age, whereas both p27 null and heterozygous mice developed an average of one malignant tumor per mouse by 30 weeks of age (Figure 1f ). These tumors where characterized by marked cellular atypia and local invasion, indicating that p27 deficiency increased malignant tumor progression.
Tumor suppression by p27 is cell autonomous Detection of mutations in cancer genes in tumors is evidence for a cell autonomous mechanism of action, as opposed to a systemic, indirect effect of p27 deficiency in the whole organism. However, mutations in the CDKN1B gene encoding p27 are rarely observed in tumors. Forced expression of p27 can inhibit tumor cell proliferation, and mice lacking p27 are tumor prone. However, this evidence is insufficient to prove that p27 suppresses tumors through a cell autonomous mechanism, and other approaches are required to establish this conclusively. We used a neonatal lung tissue transplantation model to address this. Lung tissue from neonatal p27-deficient or wild-type mice was transplanted to the ear of adult wild-type recipients. After engraftment, mice were treated with urethane, and transplant size was measured up to 30 weeks. Tumors developed from B50% of transplants from p27À/À (10/19) or p27 þ /À mice (19/39) compared with only 25% (5/20) from p27 þ / þ mice ( Figure 2a ). Tumors were larger from both p27À/À and p27 þ /À transplants ( Figure 2b ). Histological evaluation indicated that the majority of tumors were bronchioalveolar adenomas and carcinomas. Thus, cells lacking p27 are more susceptible to tumorigenic outgrowth than are p27-intact cells, indicating a cell autonomous mechanism of tumor suppression by p27.
Mutation of Kras in urethane-induced lung tumors
Sequence analysis of lung tumor DNA revealed that 80% of urethane-induced tumors had a CAA-to-CTA transversion mutation at codon 61 of the Kras gene, resulting in a Q61L amino acid change (Figure 3a ). The frequency of this mutation was similar in tumors from A/J, B6 and B6/129 strains. The frequencies of Kras mutations were also similar in tumors from p27 þ / þ , þ /À and À/À mice ( Figure 3b ).
Nuclear exclusion of p27 protein in lung tumors
As p27-deficient mice showed increased susceptibility to urethane-induced lung tumors, we examined the status of p27 protein in lung tumors from p27-intact mice. Staining of tissue sections with a monoclonal anti-p27 antibody revealed prominent nuclear p27 staining in normal lung parenchymal cells but reduced nuclear p27 in tumor cells (Figure 4a ). Western blot analysis of nuclear and cytoplasmic fractions prepared from frozen tissues revealed that tumors exhibit reduced nuclear p27 while retaining the cytoplasmic pool ( Figure 4b ). Quantitation with densitometry confirmed that the ratio of nuclear to cytoplasmic p27 was markedly reduced in tumors compared with that in normal lung (Figure 4c ). Therefore, both mutation of Kras and aberrant subcellular localization of p27 protein are cardinal features of this tumor model.
As both Ras mutation and altered p27 expression are consistently observed together, we asked whether oncogenic signals emanating from mutant Ras protein actively drive p27 mislocalization. We compared the phosphorylation status of specific residues of p27 (Ser10, Thr187 and Thr197) shown to be involved in the regulation of cellular localization as well as upstream candidate regulators between normal lung and tumor lysates.
Ras signaling is expected to induce cyclin D1, activate Cdk2 and drive cell cycle progression. Cdk2, in turn, is known to phosphorylate residue Thr187, targeting p27 for Jab1-mediated export and Skp2 dependent degradation (Sheaff et al., 1997) . We found an increase in both cyclin D1 and Cdk2 kinase activity in tumor extracts, consistent with the enhanced proliferation of lung tumor cells (Figure 5a ). We also observed an increase in Jab1 and Thr187 phospho-p27 in cytoplasmic fractions of lung tumors (Figure 5b ). The cytoplasmic levels of two ubiquitin ligases for p27, Skp2 and Kpc, were similar between tumor and normal tissue, suggesting that proteasome-dependent degradation of p27 through upregulation of Skp2 or Kpc may not be the major pathway to regulate p27 abundance in this tumor model.
Ras also signals through PI3K to activate Akt, which in turn can phosphorylate p27 at multiple sites including Figure 5 Post-translational regulation of p27 in lung tumors (a) Increased Cdk2 activity in lung tumors from wild-type mice versus normal lung using histone H1 as a substrate. Western blot of whole cell lysates shows Cdk2 protein levels unchanged and an increase in cyclin D1 in lung tumors compared with that in normal lung. (b) Western blot of total p27, phospho-T187 p27, Jab1, KPC and Skp2 in tumors and normal lung, with lamin B1 and b-tubulin as nuclear and cytoplasmic fractionation controls. Note increase in p-T187 p27 in cytoplasmic fractions compared with normal lung. n, nuclear extracts; c, cytoplasmic fractions. (c) Western blot of p-T198 p27, p-S10 p27 and 14-3-3-y. Note increased p-T198 p27 in cytoplasmic tumor fractions. Ser10, Thr157 (in human but not in mouse) and Thr198 (Thr197 in the mouse), each of which has been shown to promote nuclear-to-cytoplasmic shuttling (Susaki and Nakayama 2007) . Phosphorylated Ser10 p27 was found in nuclear and cytoplasmic fractions and did not seem to differ between normal and tumor extracts (Figure 5c ). However, as total nuclear p27 is markedly reduced in nuclear fractions from tumors, the proportion of p27 that is phosphorylated within tumor nuclear pools could be increased.
Levels of phospho-Thr198 p27 were markedly increased in lung tumors, notably in the cytoplasmic fraction (Figure 5c ). The levels of 14-3-3, which binds to cytoplasmic p27 phosphorylated at Thr198 (Fujita et al., 2003) , were also modestly elevated, suggesting a plausible scenario of Akt-dependent phosphorylation of Thr198 p27 and cytoplasmic retention of p27 by 14-3-3. These data together indicate that p27 is phosphorylated at multiple sites in lung tumors, one or more of which could signal nuclear export and cytoplasmic retention.
Reduction of p27 transcript in lung tumors
Although most studies have focused on post-translational regulation of p27 abundance, transcriptional control is also documented (Philipp-Staheli et al., 2004) . Quantitative real-time PCR revealed a five-to tenfold reduction in p27 mRNA transcript in 13 out of 13 lung tumors examined as compared with that in normal lung tissue (Figure 6a ). Signaling from Ras has been linked to p27 transcription through Akt-dependent phosphorylation of Forkhead transcription factors . Lung tumor extracts showed an increase in active phospho-Akt (Figure 5c ), as well as in phosphorylated cytoplasmic FOXO1 and FOXO3a. Phosphorylated FOXO4a, by contrast, shows equivalent expression in tumor and normal lung (Figure 6b ). These data are consistent with the idea that oncogenic Kras signaling through PI3K activates Akt, which phosphorylates FOXO transcription factors, resulting in their retention in the cytoplasm, thereby reducing p27 transcription.
In summary, p27 expression in lung tumors is altered in at least two ways, namely increased phosphorylation leading to nuclear exclusion and reduced transcription. Both mechanisms could be due to Ras signaling through Akt.
Inhibition of PI3K and Akt restores p27 levels in tumors
As the gene encoding p27 is intact in tumors, we asked whether its expression could be restored by pharmacologically blocking pathways leading to its misregulation. As Akt has a role in both transcriptional and post-translational regulation of p27, we used the PI3K inhibitor LY294002 to inhibit the ras signaling pathway downstream of PI-3K, which would include inhibition of Akt-dependent mechanisms. Treatment of the mouse lung tumor cell line SP10 with LY294002 led to a reduction of phospho-Akt, a reduction in phospho-FOXO, and an increase in both p27 transcript and protein levels (Figures 7a and b) . Therefore, inhibition of the PI-3 kinase pathway can enhance p27 levels in tumor cells by increasing p27 transcription.
We next treated lung tumor-bearing A/J mice with LY294002 and analysed tumors for short-term changes in Akt signaling and p27 expression. Western blot analysis of tumor lysates showed a marked reduction of phospho-Akt and phosphorylated FOXO in inhibitortreated mice compared with tumors from vehicle-treated mice (Figure 7c ), whereas total cellular levels of Akt remained unchanged. This shows that LY294002 treatment effectively inhibited the PI-3K-Akt-FOXO signaling cascade in lung tumors in vivo. Next, we examined p27 expression and phosphorylation. LY294002 treatment reversed the nuclear exclusion of p27 in tumors, as revealed by both western blots of tumor lysates ( Figure 7c ) and immunohistochemistry of lung tumor sections (Figure 7d ). Relative to untreated tumors, tumors from LY294002-treated mice showed equal nuclear/cytoplasmic distribution of p27 and more prominent nuclear staining for p27. As LY294002 inhibits Akt, and Akt can phosphorylate p27 directly, we examined the phosphorylation status of p27. Western blotting of lysates from inhibitor-treated tumors showed a reduction in both cytoplasmic phospho-Thr198 and phospho-Ser10 p27 (Figure 7e ). Together, these findings indicate that aberrant expression of p27 in tumors is an active process regulated by the PI3K-Akt pathway, and that the mislocalization of p27 in tumors can be reversed through the use of pathway-specific inhibitors. 
Discussion
These studies show that p27 acts as a barrier to the growth and malignant progression of Kras-driven NSCLC. Both homozygous and hemizygous germline deletion of p27 led to an increase in both the size and malignancy of tumors. The observation that the average number of tumors in wild-type mice at 50 weeks was similar to the number of tumors in p27-deficient mice at 30 weeks, together with the observation that tumor suppression by p27 is cell autonomous, argues that the primary effect of p27 is to inhibit the clonal expansion of initiated tumor cells. Tumors from all p27 genotypes harbored mutations in the Kras oncogene, establishing that p27 specifically inhibits Kras-driven tumor growth. The ubiquitous reduction of nuclear p27 in tumors further implies that cell cycle inhibition by p27 is a critical barrier to be overcome for such clonal expansion.
p27 and malignant progression
In addition to inhibiting tumor growth, p27 suppressed malignant lung tumor progression. By 30 weeks of age, 67% of p27-deficient mice had malignant disease, averaging one adenocarcinoma per mouse, whereas no carcinomas were observed in p27-intact mice. It is at present not clear whether this is due to increased tumor growth, leading to an increase in the rate of tumor evolution toward malignancy, or if it is a more direct consequence of p27 functions; for example, due to loss of differentiation or increased invasion. p27 can induce cell differentiation in vitro (reviewed in Philipp-Staheli et al., 2001) , and p27 deficiency leads to impaired differentiation of several cell types in vivo (Nakayama et al., 1996; Casaccia-Bonnefil et al., 1997; Tong et al., 1998; Zindy et al., 1999) . Although the mechanisms by which p27 can trigger differentiation are poorly understood, p27-induced cell cycle exit seems to be tightly linked to terminal differentiation. p27 also has a role in cell migration, independent of its Cdk inhibitory function (Besson et al., 2004a) . p27 has been shown to inhibit cancer cell invasion (Yuan et al., 2007; Schiappacassi et al., 2008) by binding to microtubule destabilizing protein, stathmin (Baldassarre et al., 2005) . On the other hand, a promigratory role for cytoplasmic p27, through interaction with the Rho family of GTPases and the cytoskeleton, has also been described (McAllister et al., 2003; Besson et al., 2004b) . Hence, tumors with reduced or mislocalized p27 may have impaired capacity to differentiate and/or enhanced migratory ability, thereby increasing their malignant behavior.
Malignant tumor progression due to reduced p27 has been documented in other mouse cancer models (Philipp et al., 1999; Philipp-Staheli et al., 2002; Shaffer et al., 2005) , indicating that this is a characteristic trait of tumor suppression by p27. In human cancer, including NSCLC, reduced p27 expression correlates with higher tumor grade and stage, features that incorporate differentiation, invasion and metastasis (Chu et al., 2008) . Together, this indicates that p27 is a barrier to malignant progression and the misregulation of p27 in tumors is causally linked to tumor aggressiveness.
p27 misregulation in tumors
Having established that p27 inhibits both the growth and malignant progression of NSCLC, we next examined the mechanism by which tumors circumvent p27. Lung tumors showed a consistent reduction in the nuclear pool of p27, while largely retaining cytoplasmic expression, as well as a marked reduction of mRNA transcript. Thus, transcriptional control as well as subcellular localization contribute to a reduction of nuclear p27 in tumors, which can lead to increased CDK activity. Activating mutations in Kras were also cardinal features of this tumor model, suggesting a mechanistic link between Kras signaling and p27 loss. Indeed, an emerging model to explain the basis of cooperation between oncogene activation and tumor suppressor gene loss posits that oncogenes directly signal to tumor suppressor genes. The Ras effector, Akt, has been shown to regulate p27 at multiple levels; therefore, we asked whether p27 misregulation in tumors is a direct consequence of increased Akt signaling. p27 can be barred from the nucleus by pathways involving phosphorylation at Ser10, Thr157 (human but not mouse) and Thr198 (T197 in the mouse), all of which have been reported as Akt targets. We did not observe significant changes in abundance of phospho-Ser10 p27 in lung extracts. However, as the total nuclear p27 levels were decreased in tumors, it is possible that the ratio of phospho-Ser10 p27 to total p27 is increased in these tumors. Akt can also phosphorylate p27 on Thr198 and promote binding to 14-3-3 in the cytoplasm (Fujita et al., 2003; Motti et al., 2004 Motti et al., , 2005 . Lung tumors showed a marked increase in phospho-Thr197 p27, specifically in the cytoplasmic pool, together with a modest increase in 14-3-3, suggesting that phosphoThr198 may direct nuclear export and increase stability of p27 in the cytoplasm. Indeed, inhibition of Akt in both mouse lung tumor cell lines and in tumor-bearing mice led to a reduction in phospho-Ser10 and phosphoThr198 p27, and redistribution of p27 to the nucleus.
Akt is also a key player in mediating signaling from Ras through the FOXO transcription factors to regulate p27 transcription . Increased phosphorylation of FOXO proteins was seen in cytoplasmic fractions from lung tumors, correlating with reduced p27 mRNA levels. LY294002 reduced phosphorylation of both Akt and FOXO, and increased p27 transcript and nuclear p27 protein levels. Together these findings show that Ras signaling through the PI3K/Akt pathway regulates p27 abundance and localization at both the transcriptional and post-translational levels.
In summary, p27 acts as a potent barrier to Krasinitiated NSCLC that must be overcome for efficient clonal expansion and malignant progression. However, in contrast to most known tumor suppressors, which are inactivated by mutation, p27 reduction is an active and reversible process; in this case, mediated by oncogenic signaling. If a similar mechanism occurs in human lung cancer, this would create a window of opportunity for therapeutic intervention.
Materials and methods
Mice
Experiments were approved by the FHCRC Institutional Animal Care and Use Committee. Two cohorts of 129 Â C57BL/6J F 1 p27À/À, p27 þ /À and p27 þ / þ mice (Fero et al., 1996) , as well as C57BL/6J and A/J mice were treated with urethane (1 mg/g bodyweight, i.p.) at 12 days of age. Cohorts were killed at 30 or 50 weeks of age. Tumors visible on the surface of all lung lobes were counted and measured using a dissecting microscope. Normal and tumor tissues were either snap frozen in liquid nitrogen for DNA, RNA and protein extraction or fixed in neutral buffered formalin. Fixed tissue was processed and stained with H&E for histological examination. DNA for genotyping was obtained by digestion of tissue with proteinase K in InstaGene Matrix solution (Bio-Rad, Hercules, CA, USA). Each mouse was genotyped by PCR using primers specific for the wildtype or neo interrupted p27 locus (Fero et al., 1996) .
Kras sequence analysis
Genomic DNA was isolated from lung tumors using the QIAGEN QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). The Kras locus at codon 61 was amplified using primers 5 0 -GACTCCTACAGGAAACAAGT-3 0 and 5 0 -GAAGATA TTCACCATTATAG-3 0 (You et al., 1989) by PCR, and sequenced using the Big Dye Sequencing protocol (PEBiosystems, Foster City, CA, USA).
Western blot analysis
Nuclear and cytoplasmic protein extracts were prepared as described (Schreiber et al., 1989) , with modifications (PhilippStaheli et al., 2002) . Protein concentrations were standardized using the Bradford assay (Bio-Rad), and equal loading was confirmed by Ponceau S staining of PVDF membranes after blotting (Immun-Blot PVDF membrane, Bio-Rad). The following antibodies were used for western blotting: p27 (sc-528), phospho-Thr187 p27 (sc-16324), phospho-Ser10 p27 (sc-12939), cyclinD1 (sc-755), cdk2 (sc-163), Jab1 (sc-9074), 14-3-3 y (sc-732), b-tubulin (sc-9104) and lamin B1 (sc-20682) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). p45/Skp2 antibody (ab19877) was purchased from Abcam (Cambridge, MA, USA) and the phospho-Thr198 p27 (AF3994) purchased from R&D Systems (Minneapolis, MN, USA). The anti-KPC1 antibody (H00063891-A01) was obtained from Novus Biologicals (Littleton, CO, USA). Akt phospho-specific (9271, 9275) and FOXO family (9464, 9466, 9471) antibodies were purchased from Cell Signaling (Beverly, MA, USA).
Histopathology and immunohistochemistry
Lung lobes with embedded tumors were removed and fixed in 10% neutral buffered formalin for 4-6 h, processed and embedded in paraffin.
Step sections were made, with every fifth section stained with H&E for the most accurate histological quantification of tumor multiplicity and malignancy. All slides were reviewed by a pathologist (SK) blind to the genotype. Diagnosis of adenoma was based on discrete, well-demarcated foci consisting of a uniform population of epithelial cells with round nuclei and a moderate amount of eosinophilic cytoplasm. Compared with adenomas, adenocarcinomas showed greater cellular atypia, regional variation of growth patterns, increased mitotic activity, and local invasion into adjacent bronchioles or vessels. Immunohistochemistry for p27 was performed as described (Philipp-Staheli et al., 2002) using a mouse monoclonal antibody from Neomarkers (Fremont, CA, USA). Controls included no primary antibody and/or normal rabbit serum, and tissues from p27 null mice.
Histone kinase assay
Protein extracts were prepared as described above and stored in 50% glycerol. In total, 400 mg of protein were incubated on ice in 500 ml RIPA buffer containing Cdk2 antibody. Then 30 ml of washed Protein A-Sepharose beads were added, and the reaction was rotated for 1 h at 4 1C. Beads were washed twice in RIPA and once in a buffer containing 25 mM Tris HCl (pH 7.5), 70 mM NaCl, 10 mM MgCl 2 and 1 mM DTT. The beads were then incubated with Histone H1 as a substrate and 32 P-gATP for 30 min at 37 1C. The reaction was stopped by the addition of sample buffer, denatured for 5 min at 95 1C and the protein separated on a 12% SDS acrylamide gel run for 45 min at 150 volts. The gel was washed, fixed and exposed to X-ray film to visualize bands.
Real-time PCR assay
The relative levels of p27 mRNA were assessed using RT-PCR as described (Philipp-Staheli et al., 2004) , using the forward primer 5 0 -AGGCTGGGTTAGCGGAGC-3 0 ; reverse primer 5 0 -GAACCGTCTGAAACATTTTCTTCTGT-3 0 ; and probe 5 0 -FAM-ACCTTGCTGCAGAAGATTCTTCTTCGCAA-TA MRA-3 0 .
Tumor DNA isolation and LOH analysis DNA was extracted from frozen tumors using Bio-Rad InstaGene Matrix, and p27 PCR conditions are available on request. PCR products were run on a 1% agarose gel stained with ethidium bromide.
Ear engraftment
Lungs were removed from neonatal mice derived from NIH p27 þ /À Â B6/129 p27 þ /À crosses, and cut into 2-mm 3 sections and kept on ice. Recipient NIH wild-type adult mice were anesthetized with avertin. A small pouch was made in both the ears using a scalpel and scissors. A 2-mm 3 section of lung was inserted, and the pouch was sealed with super glue. For a given recipient, transplant of a different p27 genotype in each ear served as a control. Mice were injected with urethane once a week for 6 weeks (0.25 mg/g body weight i.p.). The ear grafts were measured every other week and mice were killed at 30-38 weeks, and tissues were processed as described above.
PI3K inhibition SP10 lung tumor cells (ATCC), derived from a spontaneous lung tumor from an A/J strain mouse, were grown to 70% confluence, serum starved overnight and then serum containing media with 50 mg/ml LY294002 (Sigma, St Louis, MO, USA) was added. Cells were harvested at 1, 2, 4, 6 and 18 h post treatment and whole cell lysates were made using buffer containing 150 mM NaCl, 50 mM Tris pH 8 and 1% NP-40. Cells not subjected to serum starvation or inhibitor treatment were used as controls in western analysis. For in vivo studies, 9-month old lung tumor-bearing A/J mice were injected with LY294002 (100 mg/kg body weight, i.p.) or DMSO thrice over a 6-h time period.
